Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today, FDA advisers are convening to discuss Lykos Therapeutics’ MDMA-assisted psychotherapy for people with PTSD. It’s a critical meeting — MDMA could be the first Schedule I psychedelic to be deemed to have a medical use. Our reporters Olivia Goldhill and Meghana Keshavan will be live-blogging the meeting all day — tune in here.
The need-to-know this morning
- It’s a clinical trial readout kind of morning, starting with Viking Therapeutics and its MASH treatment, called VK2809, with mid-stage results.
- BridgeBio Pharma reported long-term results from a study of its drug called infigratinib for the treatment of achondroplasia, a form of dwarfism.
- Annexon Biosciences announced the outcome of a Phase 3 study in Guillain-Barré syndrome.
AZ’s CAR-T therapy shows promise in early liver cancer trial
A next-generation CAR-T therapy from AstraZeneca substantially shrunk tumors in patients with liver cancer in a small Phase 1 trial. These data are part of a big showing by AstraZeneca at ASCO this year — the company had two plenary presentations already.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect